BishtRef
Articles Journals Publishers Authors Subjects Most Cited New Papers Year Stats Open Access
journal article Open Access Jun 26, 2022

Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes

Roopa Mehta Liana K. Billings ORCID Andreas Liebl Tina Vilsbøll ORCID
Diabetic Medicine Vol. 39 No. 9 · Wiley
View at Publisher Save 10.1111/dme.14901
Abstract
AbstractAimsTwo fixed‐ratio combinations (FRCs) of basal insulin and glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) are available for once‐daily use in adults with type 2 diabetes. We aimed to review the clinical evidence for the efficacy and safety of changing treatment from a basal–bolus insulin (BBI) regimen or a premix insulin to these combination treatments (fixed‐ratio or loose) and provide expert opinion on the practicalities of making such a change.MethodsRelevant clinical and trial evidence and general review articles were identified through a literature review of ProQuest (comprising BIOSIS Previews®, Current Contents® Search, Embase® and MEDLINE®) for articles published between 2009 and 2021.ResultsWe identified nine articles reporting the results of FRCs, and seven articles reporting results of loose combinations of basal insulin and GLP‐1RAs, in people who transitioned treatment from BBI or premix regimens. In most trials, combination treatment led to improved or equivalent glycaemic control, and a reduction in body weight or BMI, versus the original regimens. Some trials reported a reduction in total insulin dose. A few trials reported reduced or unchanged hypoglycaemia rates, or increased patient satisfaction, with combination therapy where these endpoints were examined. We provide guidance on transitioning of treatment and the patient types most likely to benefit.ConclusionsIn people not achieving glycaemic control with BBI or premix insulin regimens, an FRC or loose combination of basal insulin and GLP‐1RA may improve control, decrease the risk of body weight gain or hypoglycaemia and reduce the complexity of treatment.
Topics

No keywords indexed for this article. Browse by subject →

References
52
[3]
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes

Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella et al.

Diabetes Care 10.2337/dc10-1710
[14]
Novo Nordisk A/S. Xultophy.Summary of Product Characteristics;2020. (Accessed October 2020 athttps://www.medicines.org.uk/emc/product/3469.)
[15]
Novo Nordisk Inc.Xultrophy 100/3.6 highlights of prescribing information;2016. (Accessed October 2020 athttps://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208583s000lbl.pdf.)
[16]
Sanofi.Suliqua Summary of Product Characteristics;2020. (Accessed October 2020 athttps://www.medicines.org.uk/emc/product/9870/smpc#gref.)
[17]
Sanofi.Soliqua 100/33 highlights of prescribing information;2019. (Accessed October 2020 athttps://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208673s007lbl.pdf.)
[32]
Persano M "Real‐world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi‐injective insulin therapy" Eur Rev Med Pharmacol Sci (2021)

Showing 50 of 52 references

Metrics
15
Citations
52
References
Details
Published
Jun 26, 2022
Vol/Issue
39(9)
License
View
Authors
R
Roopa Mehta

Unidad de Investigación en Enfermedades Metabólicas, Departamento de Endocrinología y Metabolismo Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City Mexico

L
Liana K. Billings

Division of Endocrinology and Metabolism NorthShore University HealthSystem Skokie Illinois USA; Department of Medicine University of Chicago Pritzker School of Medicine Skokie Illinois USA

A
Andreas Liebl

Center for Diabetes and Metabolism, m&i‐Fachklinik Bad Heilbrunn Germany

T
Tina Vilsbøll

Steno Diabetes Center Copenhagen, Gentofte Hospital Gentofte Denmark

Funding
Novo Nordisk
Cite This Article
Roopa Mehta, Liana K. Billings, Andreas Liebl, et al. (2022). Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes. Diabetic Medicine, 39(9). https://doi.org/10.1111/dme.14901
Related

You May Also Like

International Diabetes Federation: a consensus on Type 2 diabetes prevention

K. G. M. M. Alberti, P. Zimmet · 2007

515 citations

Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta‐analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion

J. C. Pickup, A. J. Sutton · 2008

514 citations

Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications

W. H. Herman, R. Pop‐Busui · 2012

385 citations

High prevalence of erectile dysfunction in diabetes: a systematic review and meta‐analysis of 145 studies

Y. Kouidrat, D. Pizzol · 2017

364 citations

Measures of Psychological Well‐being and Treatment Satisfaction Developed from the Responses of People with Tablet‐treated Diabetes

C. Bradley, K.S. Lewis · 1990

290 citations